NEWS Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis 21 January 2025 LEARN MORE
NEWS Life Molecular Imaging and SOFIE announce Neuraceq® availability in Somerset, NJ 6 January 2025 LEARN MORE
NEWS Life Molecular Imaging and PharmaLogic announce Neuraceq® availability in Cincinnati, OH 28 October 2024 LEARN MORE
NEWS Life Molecular Imaging Receives FDA Fast Track Designation for [18F]PI-2620 in Tau PET Imaging Across Three Neurodegenerative Conditions 28 August 2024 LEARN MORE
NEWS Life Molecular Imaging and PharmaLogic announce Neuraceq® availability in Denver 20 August 2024 LEARN MORE
NEWS Life Molecular Imaging Announces Collaboration to Provide Both its Amyloid and Tau PET Imaging Agents for Research of Alzheimer’s Disease in a Large Consortium Clinical Trial Sponsored by National Institute on Aging 23 July 2024 LEARN MORE
NEWS Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Mobile, AL 9 July 2024 LEARN MORE
NEWS Life Molecular Imaging Enters Agreement With Lantheus to Sub-License its Radiotheranostic Agent RM2 Targeting GRPR in Prostate and Breast Cancers 27 June 2024 LEARN MORE
NEWS Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland 4 April 2024 LEARN MORE
NEWS Life Molecular Imaging and Oryx Isotopes Industrial Company announce a Strategic Partnership for the Production and Distribution of Florbetaben (18F) in the Kingdom of Saudi Arabia and other countries in reach 6 February 2024 LEARN MORE
